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a.poole@bris.ac.uk (A.W. Poole).Platelets tightly regulate haemostasis and arterial thrombosis. Protein kinase C (PKC) is involved in
most platelet responses implicated in thrombus formation. Recent pharmacological and mouse
gene knockout approaches show that the conventional PKC isoforms and the novel PKC isoforms
contribute in distinct ways to these platelet responses. We hypothesize that, in platelets and other
cells, the characteristic functions of PKC isoforms are established through unique activation mech-
anisms and unique interacting protein partners, which result in isoform-speciﬁc patterns of sub-
strate phosphorylation. For identifying the substrate proteins in a living cell, new methodology is
available and discussed.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Platelets are central to normal haemostasis and arterial throm-
bosis. Although it has been known for many years that the protein
kinase C (PKC) family regulates many cellular functions, recent re-
search provides detailed insight into the roles of individual protein
kinase C (PKC) isoforms in the activation of human and mouse
platelets. In particular, it has become clear that different isoforms
have distinct, non-redundant functions. Hence, the earlier estab-
lished general concept of PKC structure-function relationships
now can be applied to individual PKC isoforms [1,2]. We hypothe-
size that the functional diversity of PKC isoforms is determined by
their variation in structure and phosphorylation, with as a conse-
quence individual temporal and spatial activation patterns. We
also discuss strategies for identifying the substrates of each iso-
form within its appropriate cellular context. Given the ubiquitous
expression of most PKC isoforms, the new insights from platelets
will help to understand the roles of the kinases in the biology of
other mammalian cells.
Members of the subfamilies of conventional PKC (cPKC), novel
PKC (nPKC) and atypical PKC (aPKC) isoforms share a well con-chemical Societies. Published by E
ventional and novel protein
rotein; DAG, diacylglycerol;
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ersity.nl (J.W.M. Heemskerk),served catalytic domain with binding sites for ATP and protein
substrates (Fig. 1). In all PKC isoforms, the so-called pseudosub-
strate site, which docks into the catalytic moiety, needs to be dis-
placed by conformational changes to allow protein kinase activity.
This has been most recently demonstrated in the ﬁrst full-length
PKC crystal structure, for PKCbII [3]. In all isoforms, the pseudo-
substrate site is located in the region immediately N-terminal to
the C1 domain, and contains an Ala instead of Ser/Thr, meaning
that it cannot be phosphorylated [1]. Because of these similarities
between all PKC isoforms, it is understood that functional diver-
sity should come from variation in their regulatory moieties
[2,4,5].
Platelets express the cPKC isoforms, PKCa and b, which com-
prise a regulatory moiety with a tandem C1 domain, capable of
binding diacylglycerol (DAG), and a C2 domain, binding Ca2+ and
phosphatidylserine (PS) [6–8]. Platelets furthermore express nPKC
isoforms, which also have a tandem C1 domain, but differ by the
presence of a C2-like domain that no longer binds Ca2+ (Fig. 1).
Whereas PKCd and h are readily detectable in human and mouse
platelets, there expression level of PKCg is unclear [8–11], and
expression of PKCe is conﬁned to mouse platelets [8]. Of the aPKC
isoforms, which lack a C2 domain and contain a shortened C1 do-
main that does not bind DAG, only PKCf has been identiﬁed in
platelets [6,11], although its expression level is uncertain. Consid-
ering the structural diversity of the regulatory moieties, we
hypothesize that these PKC domains regulate the establishment
of unique activation mechanisms and unique sets of interacting
protein partners for each isoform, with as a consequence different
characteristic functions in the living cell.lsevier B.V. All rights reserved.
NN
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Fig. 1. Domain structure and molecular interaction sites of conventional, novel and atypical PKC isoforms. The various PKC family members share a common catalytic moiety
with C3 and C4 domains binding ATP and protein substrates, respectively. The substrate binding site interacts with a pseudosubstrate domain (P) in inactive forms of the
kinases. PKC members differ in their regulatory moieties. The cPKC isoforms contain two C1 domains that form a diacylglycerol (DAG)-binding site, and a Ca2+/PS-binding C2
domain. nPKC isoforms typically have a Ca2+-insensitive C2-like domain, while aPKC isoforms lack the C2 domain and contain a C1 domain that is insensitive to DAG. These
regulatory domains also mediate isoform-speciﬁc binding to C-kinase interacting proteins (C-KIP), including receptors for activated C-kinase (RACK). Modiﬁed from Refs.
[7,50].
1712 J.W.M. Heemskerk et al. / FEBS Letters 585 (2011) 1711–17162. PKC isoform speciﬁcity in platelet activation processes
Signalling by phospholipase C, to produce inositol 1,4,5-tris-
phosphosphate and diacylglycerol (DAG), has been recognized as
a central pathway in almost every platelet response [12]. Thus,
PKC activation regulates: (i) platelet adhesiveness by afﬁnity regu-
lation of integrins at the membrane surface; (ii) platelet shape by
controlling cytoskeleton dynamics and ﬁlopod and lamellipod for-
mation; (iii) secretion of auto- and paracrine agents by promoting
exocytosis of storage granules; (iv) synthesis of prostaglandins and
thromboxanes; (v) cytosolic Ca2+ ﬂuxes; and (vi) surface mem-
brane exposure of procoagulant PS (Table 1). Accordingly, PKC acti-
vation is a crucial step in platelet adhesion to the extracellular
matrix and to other blood cells, in platelet-dependent coagulant
activity, and in platelet aggregate and thrombus formation. As a
whole, the functions of PKC family members however are complex,
since they are reported both to positively and negatively regulate
integrin activation and secretion, but negatively regulate Ca2+ sig-
nalling and procoagulant activity [12,13]. A working hypothesis is
therefore that some isoforms of PKC may be responsible for the po-
sitive and other isoforms for the negative regulatory effects,
although their roles may also differ from one agonist to another.Table 1
Functions of PKC isoforms in platelets and other blood cells. Functions were established u
platelets, using pharmacological inhibitors with isoform selectivity: Gö6976 (e.g., blocking
Response (agonist) Conventional Novel
a b d
Platelets
Membrane translocation (GPVI, Thr) + o/+
Integrin activation (GPVI) + + o
Filopod formation (GPVI) o –
Lamellipod formation (ﬁbrinogen) o +
Exocytosis, a granules (GPVI, Thr) + + o
Exocytosis, d granules (GPVI, Thr) + –/+
Thromboxane production (GPVI, Thr) –/+
Calcium ﬂux (GPVI) + + o
Procoagulant activity (GPVI) + + o
Platelet aggregation (ADP, GPVI, Thr) + + –
Thrombus formation (GPVI) + + –/o
Other blood cells
Exocytosis lytic granules (T cells) + +
Exocytosis tertiary granules (neutrophils) + +
Exocytosis (endothelial cells) +
Abbreviations: +, increase; –, decrease; o, no effect; Thr, thrombin. ⁄Reported in one papInvestigations using genetically modiﬁed mice and supported
by studies with PKC isoform-selective inhibitors have yielded
detailed insight into the contribution of speciﬁc cPKC and nPKC
isoforms in these processes (Table 1). Experiments using Prkca/
and Prkcb/ mice point to non-redundant positive roles for both
cPKC isoforms in the majority of platelet responses. Deﬁciency in
either PKCa or PKCb markedly diminishes collagen-dependent
thrombus formation, accompanied by reductions in Ca2+ rise, inte-
grin activation, granule secretion and procoagulant activity
[14,15]. Inhibitors blocking PKCa and/or PKCb isoforms, cause sim-
ilar effects on human platelets (Table 1). The likely mechanism is
reduced signalling via the main collagen receptor, glycoprotein VI
(GPVI) [13,16]. Quantitatively, the contribution of PKCa seems to
be stronger than that of PKCb, which agrees well with the reported
relative expression of the two isoforms. PKCa in particular has a
major role in regulating platelet dense granule formation and
secretion [14,15], whereas PKCb is a recognized regulator of inte-
grin-dependent (outside-in) signalling [9].
Given the limited speciﬁcity of the pharmacological PKCd inhib-
itor rottlerin, the role of this isoform can best be understood from
studies with Prkcd/ mice. In response to collagen, PKCd nega-
tively regulates ﬁlopod formation, which may explain its moderatesing mice deﬁcient in the concerning isoforms. Data in bold are conﬁrmed for human
PKCa/b), b-inhibitor (PKCb>a), rottlerin (PKCd), h-inhibitor (PKCh).
Atypical Refs.
eM g h f i
+ + + [19,36,37]
– [6,14,17]
+ [15,17]
+ [9,21,23]
–/+ [11,14,15,21]
+ o [6,8,15,17,21]
+ [10,18,22]
– [13,14,20]
– [14,20]
+ o –(+⁄) [8,10,11,14,15,17]
o – (+⁄) [8,14,15,18,21,22]
+ [25,26,51]
[27]
[52]
er.
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tion induced via GPVI [14,17,18]. By contrast, PKCd has a positive
role in thrombin-induced secretion and thromboxane production
[6,18,19]. The isoform PKCe, expressed in murine but not human
platelets, promotes platelet responses to GPVI but not to thrombin,
subsequent to its phosphorylation on tyrosine [8]. One report,
assessing PKCg phosphorylation, provides evidence that, in ADP-
stimulated human platelets, this isoform supports thromboxane
production, but not platelet aggregation [10]. Expression effects
of PKCg and f isoforms have not been conﬁrmed in deﬁcient mice.
The isoform with a most clearly established negative regulation
of collagen-dependent thrombus formation is PKCh, as concluded
from the analysis of Prkcq/ mice and the use of h-inhibitor (Ta-
ble 1). Following GPVI activation, PKCh suppresses Ca2+ entry and
Ca2+-dependent processes, such as a-granule secretion and PS
exposure [14,20]. As a consequence, this isoform has a markedly
suppressive role in collagen-dependent thrombus formation
[14,21]. By contrast, in thrombin-stimulated platelets, PKCh posi-
tively contributes to granule secretion, thromboxane production
and aggregation [11,22]. PKCh also promotes lamellipod formation
of platelets on ﬁbrinogen [21,23]. These ﬁndings highlight the dif-
ferences in regulation of platelet activation via protein tyrosine ki-
nase-dependent pathways (GPVI) and G-protein coupled receptor
pathways (ADP and thrombin receptors). Involvement of the latter
may explain why one publication has denoted a positive role for
PKCh in thrombus stabilization [22] and why Prkcq/ mice show
a prolonged tail bleeding time [11].
Interestingly, pan-PKC inhibitors such as Ro-318425 and GF-
109203X have profound inhibitory effects on platelet aggregation,
integrin activation and secretion, but enhance agonist-induced
Ca2+ responses and procoagulant activity [13,14,24]. In general,
these effects are larger in comparison to single gene ablation. This
maypoint to (partial) redundancy inactionmechanismbetweendif-
ferent (related) PKC isoforms, but data from multi-gene knockouts
supporting this are lacking yet. Alternative explanations can not
be ruled out, e.g., that pan-inhibitors abolish cross-talk or cross-net-
work phosphorylation events involving different PKC isoforms.
When analysing genes using a whole mouse gene modiﬁcation,
or ablation, approach, it is important to bear in mind secondary
consequences of genetic modiﬁcation, for instance changes in
expression of related genes and developmental defects. For this
reason it is essential to verify that other key regulators of the stud-
ied signalling pathway are expressed to normal levels. It is also
important to assess platelet morphology and structure. One exam-
ple that highlights this is that ablation of the Prkca gene for PKCa
causes a marked reduction in numbers of platelet dense granules,
but not a-granules [15].
Data from other blood cells are still scarce, but a few reports
show that granule secretion in cytotoxic T cells and neutrophils
is mediated by PKCa (as in platelets) and by PKCd [25–27]. Taken
together, members of the cPKC and nPKC subfamilies appear to
have, at least in part, non-redundant roles in cytosolic signalling
processes. In particular for platelets stimulated via GPVI, the cPKC
isozymes act in a stimulatory manner, whereas the nPKC isoforms
have a suppressive effect on platelet function and thrombus
formation.3. Phosphorylation as a prerequisite for activation of PKC
isoforms
Phosphorylation of PKC is an important control mechanism of
kinase activity, e.g., by altering the accessibility of protein sub-
strates to the kinase domain. Different PKC isoforms are likely to
be subjected to dissimilar phosphorylation events. According to
the classical scheme, a three-step sequence of phosphorylationevents during maturation is required for producing active PKC
forms [28,29]. For PKCb it was established that a conserved Thr
in the catalytic moiety around amino acid residue 500 becomes
phosphorylated by phosphoinositide-dependent kinase-1 (PDK1),
after which two Thr or Ser residues around amino acid residue
650 are phosphorylated by mammalian target of rapamycin com-
plex 2 (mTORC2) [30,31]. This scheme may also be applicable to
other cPKC and nPKC family members, which have corresponding
phosphorylation sites (Supplementary Table 1).
Recent work on platelets and other cells has shed new light on
this phosphorylation pattern in particular for nPKC isoforms. In
platelets, it is reported that agonist stimulation leads to phosphor-
ylation of the ‘PDK1 site’ in the substrate-binding domain of PKCd
at Thr505 and PKCh at Thr538 [10,22,32], as has been observed in T-
lymphocytes previously [33]. Furthermore, these nPKC isoforms
show other, unique tyrosine phosphorylation events. Protein ki-
nases of the Src family mediate tyrosine phosphorylation of PKCd
on at least two different sites, Tyr311 and Tyr565, after platelet stim-
ulation with phorbol ester or other agonists [32,34]. In human
platelets tyrosine phosphorylation of PKCd is transient upon acti-
vation, while in mouse platelets it is sustained [8]. For this isoform,
it was established that agonist-induced phosphorylation regulates
the kinase activity, but not the translocation from cytosol to mem-
brane [34]. In mouse platelets, PKCe seems to be constitutively
phosphorylated on tyrosine [8]. In human platelets, however,
phosphorylation of PKCh at Tyr90 in the regulatory domain can be
evoked by GPVI- or integrin-induced stimulation [23]. Similarly
in T-cells, PKCh activation depends on tyrosine phosphorylation
by Src family kinases [35]. Importantly, tyrosine phosphorylation
of nPKC species may provide a means for isoform-speciﬁc signal-
ling, when this allows recruitment of the phosphorylated PKC to
SH2 or PTB domain-containing proteins, for instance such as pres-
ent in the assembling GPVI signalosome.4. Spatio-temporal activation and interaction patterns of PKC
isoforms
In vitro, the PKC familymembers show broadly overlapping sub-
strate speciﬁcities, in agreement with the high sequence identity of
their catalytic moieties. The recognition that they have non-redun-
dant roles in many cellular functions points to a well-controlled
regulation of their localisation and perhaps temporal activation
within the cell, to allow distinct ways of signal propagation. Here,
we hypothesise that even within the small volume of a platelet
(2–3 lm in diameter, 8–12 ﬂ in volume), different localisation
and activation patterns determine the precise roles of PKC family
members (Fig. 2). Nevertheless, partial redundancy in action mech-
anism between different (related) PKC isoforms may exist.
The lack of a functional Ca2+ binding site in nPKC isoforms sug-
gests a difference in activation mechanism in comparison to cPKC,
in particular in response to Ca2+-mobilising, DAG-producing ago-
nists. Yet, in thrombin-stimulated platelets almost all isoforms
translocate to the plasma membrane, suggesting an integrated
mechanism of kinase activation [19,36,37]. PKCd may be an excep-
tion here, in that it does not translocate in response to thrombin
itself [36], but only after integrin engagement [19]. The classical
view is that membrane translocation and DAG binding to the reg-
ulatory domain releases auto-inhibition and exposes the PKC
active site. However, common translocation does not imply trans-
location to identical membrane sites or membrane protein com-
plexes. Different sites of membrane interaction furthermore may
imply different temporal patterns of activation and stabilization
of the kinase, and different interaction sites for other intracellular
proteins. Novel, higher resolution live cell imaging approaches are
needed to conﬁrm this concept.
Fig. 2. Model of spatial and sequential activation of conventional and novel PKC isoforms in platelets. 1. Pre-phosphorylation (P) of the catalytic moiety (C3, C4 domains) is a
requirement for activation of the cPKC isoforms, which DAG/Ca2+-dependently interact with the cell membrane; and also of the nPKC isoforms, lacking the Ca2+ binding site. 2.
Receptors for activated C kinases (RACK1/2) allow interaction with cPKC and nPKC members. The nPKC isoforms may require additional phosphorylation in the catalytic and
regulatory (C1, C2, C20) moieties (P0) for full activation. 3. Tyrosine phosphorylation of nPKC isoforms mediates interaction with SH2-domain or PTB-domain scaffolding
proteins, e.g. in the platelet GPVI signalosome. 4. Speciﬁc spatial constraints and binding partners of individual cPKC and nPKC isoforms provide substrate speciﬁcity for
phosphorylation of target proteins.
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recognised anchoring sites for activated PKC. Two forms are distin-
guished, i.e., RACK1 which binds to PKC isoforms ab, and RACK2
with a higher afﬁnity for PKCe [38]. It is considered that these
anchoring proteins direct cPKC and nPKC isoforms to distinct loca-
tions in the plasma membrane, and thereby target interactions
with speciﬁc substrates. In platelets, peptides inhibiting the bind-
ing of PKCd, g or h to RACK have been used to study the roles of
these isoforms in platelet function [10,18,22]. Which of the RACK
species were targeted was however not determined. In addition
to RACK, many other interacting proteins for inactive or active
PKC isoforms have been identiﬁed in a variety of cell systems, as
summarised before [39]. Several of these may also serve as scaf-
folding proteins. Notably, tyrosine phosphorylation of nPKCs such
as PKCh may facilitate the interaction with SH2-domain signalling
proteins and explain their interaction with protein tyrosine ki-
nases, Btk and Syk [23,40].
5. Identifying the in vivo substrates of PKC isoforms
Despite a high sequence identity of the catalytic domains of
PKC, the at least partial non-redundancy of different PKC isoforms
in cell function implies that these will phosphorylate different sets
of protein substrates in vivo. Identifying the substrates of the indi-
vidual PKC isoforms, in the living cell, is therefore a major goal of
PKC biology in general, and of platelet biology in particular. A
few targets of PKC in platelets are known for many years, such as
pleckstrin [41] and myristoylated alanine-rich C kinase substrate
(MARCKS) [42]. Unspeciﬁed isoforms phosphorylate proteins of
the cytosolic SNARE complex that regulates granule secretion
[43]. In general, though, very limited information is available on
the precise substrate proteins of individual cPKC and nPKC iso-
forms and the relationship of this to cellular function.
Identiﬁcation of novel PKC substrates involves either targeted
studies on a particular protein of interest, from knowledge about
other cell types or bioinformatic predictions, or proteomics studies
where multiple proteins are screened. The classical biochemical
approach identiﬁes protein substrates by incubating cell lysates
with a puriﬁed PKC isoform in the presence of MgCl2 and
[c-32P]ATP, followed by substrate identiﬁcation by two-dimen-
sional gel electrophoresis and mass spectroscopy [44,45]. Obviousdrawbacks are the interference of protein phosphatases and other
protein kinases such as protein kinase D, which become activated
in a PKC-dependent manner [46]. Furthermore, this in vitro ap-
proach may identify substrates that, in a live-cell setting, would
not physically interact with the concerning kinase isoform.
More recently, a promising chemical-genetic approach to iden-
tifying kinase substrates has been pioneered by the Shokat group
[47]. It makes use of the conserved ATP-binding domains within
protein kinases, including a conserved Met residue that comes into
close proximity with the N6 position of ATP [44]. Mutation of this
Met to an amino acid residue with a smaller side chain (Gly or Ala)
does not abolish kinase activity, but it allows N6-modiﬁed ATP
analogues with bulky side chains, such as N6-benzoyl ATP, to ac-
cess to the ATP-binding pocket. If N6-benzoyl [c-32P]ATP is used
as substrate in place of ATP, only the mutant kinase will be able
to utilise this and only direct kinase substrates will be radiola-
belled. The labelled substrates are then identiﬁed by gel electro-
phoresis and mass spectroscopic techniques. The advantage of
this modiﬁed approach is a reduced background phosphorylation
and labelling of only direct substrates of the kinase. This method
has been used to identify novel, direct substrates of the kinase
Erk2 [48]. An improvement of this method is to use N6-benzoyl
ATPcS, which labels the substrate with a unique thiophosphate
moiety that can be puriﬁed on an iodo-acetyl resin before sub-
strate identiﬁcation [49].
Another possible route to identifying PKC substrates comes
from immuno-precipitating complexes containing individual iso-
forms with their substrates, followed by proteomic analysis. For in-
stance, this approach has been useful to identify PKCd as a
substrate of the tyrosine kinase Lyn [18].
A limitation of substrate identiﬁcation using cell lysates is the
promiscuity of kinases for substrate proteins in vitro, when freed
from the regulatory constrains present in vivo. Particularly, PKC
isoforms have largely overlapping substrate speciﬁcities in vitro.
One approach to demonstrate that a candidate substrate is phos-
phorylated in intact cells is to use phospho-motif antibodies. Such
antibodies are directed to phospho-Ser or phospho-Thr within con-
served, consensus phosphorylation sites of PKC [45]. PKC substrate
motifs are predicted from known substrates or by screening of pep-
tide libraries. Hence, antibodies raised against the generalized PKC
consensus sequence, (Lys/Arg)1–3-X-(pSer/pThr)-Y-(Lys/Arg)1–3,
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are used to detect potentially PKC-phosphorylated proteins in
platelets, which can be conﬁrmed by subsequent mass spectro-
scopic analysis. The consensus sequence varies only slightly be-
tween different PKC isoforms, meaning that antibodies may
recognise the phosphorylated substrates of multiple isoforms. Fur-
thermore, because the consensus sequence for PKC is similar to
those for the related protein kinases, PKA and PKB [5], potential
involvement of the latter kinases needs to be excluded.
Knockout mouse strains have been valuable to conﬁrm that
substrates can be targets of a speciﬁc PKC isoform within the cel-
lular context. For example, PKCa/ mouse platelets display im-
paired agonist-induced phosphorylation of SNAP23 (a member of
the SNARE complex) [15]. Platelets from PKCd/ mice show al-
tered phosphorylation of vasodilator-stimulated phosphoprotein
(VASP), a critical regulator of actin cytoskeleton dynamics, which
can explain the inhibitory role of PKCd on ﬁlopod formation [17].
In PKCe/ platelets, GPVI-induced phosphorylation of pleckstrin
is impaired [8]. Finally, PKCh/ platelets show reduced syntaxin-
4 phosphorylation (also in the SNARE complex) [22], and phos-
phorylation of WASP-interacting protein, which participates in
the regulation of F-actin nucleation and hence the dynamics of
the actin cytoskeleton [23]. However, in all these instances there
is incomplete demonstration that the substrate proteins are di-
rectly phosphorylated by the proposed isoforms. Proof should
come from a convergence of multiple lines of evidence from stud-
ies in vitro and in intact cells, described above. Further conﬁrma-
tion should come from high-resolution imaging techniques to
identify the precise spatial areas of PKC isoform localisation
in vivo by super-resolution ﬂuorescence microscopy and elec-
tron-microscopic tomography with immuno-gold labelling.6. Conclusions
We are beginning to understand the distinct, key roles of PKC
isoforms in platelet function and the molecular mechanisms of
PKC activation and regulation by which these are achieved. These
mechanisms seem to differ from isoform to isoform, although par-
tial redundancy may exist. Differences however are recognizable in
activation patterns, interacting protein partners and molecular
substrates. Future challenges are knowledge of the molecular
substrates of the isoforms, and thorough understanding of their
spatio-temporal signalling patters.
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